65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation

61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study

60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

59 - Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study

57 - A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults

56 - Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

55 - Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

54 - Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

53 - Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

52 - Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

51 - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

50 - Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

48 - Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma

47 - Dar­a­tum­umab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

46 - Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study